GlaxoSmithKline (GSK)
NYSE:GSK
Want to see GSK full AI Analyst Report?
Total Valuation
GlaxoSmithKline has a market cap or net worth of $101.79B. The enterprise value is $92.04B.
Market Cap$101.79B
Enterprise Value$92.04B
Share Statistics
GlaxoSmithKline has 2,026,583,700 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding2,026,583,700
Owned by Insiders―
Owned by Institutions8.90%
Financial Efficiency
GlaxoSmithKline’s return on equity (ROE) is 0.35 and return on invested capital (ROIC) is 16.61%.
Return on Equity (ROE)0.35
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)16.61%
Return on Capital Employed (ROCE)0.21
Revenue Per Employee475.99K
Profits Per Employee81.46K
Employee Count68,629
Asset Turnover0.54
Inventory Turnover1.52
Valuation Ratios
The current PE Ratio of GlaxoSmithKline is 12.1. GlaxoSmithKline’s PEG ratio is 0.02.
PE Ratio12.1
PS Ratio1.13
PB Ratio2.25
Price to Fair Value2.25
Price to FCF6.33
Price to Operating Cash Flow10.20
PEG Ratio0.02
Income Statement
In the last 12 months, GlaxoSmithKline had revenue of 32.67B and earned 5.72B in profits. Earnings per share was 5.64.
Revenue32.67B
Gross Profit23.65B
Operating Income8.34B
Pretax Income7.40B
Net Income5.72B
EBITDA10.40B
Earnings Per Share (EPS)5.64
Cash Flow
In the last 12 months, operating cash flow was 8.30B and capital expenditures -2.06B, giving a free cash flow of 6.24B billion.
Operating Cash Flow8.30B
Free Cash Flow6.24B
Free Cash Flow per Share3.08
Dividends & Yields
GlaxoSmithKline pays an annual dividend of $0.41, resulting in a dividend yield of 3.41%
Dividend Per Share$0.41
Dividend Yield3.41%
Payout Ratio37.28%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.30
52-Week Price Change37.31%
50-Day Moving Average53.37
200-Day Moving Average48.12
Relative Strength Index (RSI)47.60
Average Volume (3m)4.07M
Important Dates
GlaxoSmithKline upcoming earnings date is Jul 29, 2026, Before Open (Confirmed).
Last Earnings DateApr 29, 2026
Next Earnings DateJul 29, 2026
Ex-Dividend Date―
Financial Position
GlaxoSmithKline as a current ratio of 0.82, with Debt / Equity ratio of 106.74%
Current Ratio0.82
Quick Ratio0.54
Debt to Market Cap0.48
Net Debt to EBITDA1.37
Interest Coverage Ratio12.14
Taxes
In the past 12 months, GlaxoSmithKline has paid 1.11B in taxes.
Income Tax1.11B
Effective Tax Rate0.15
Enterprise Valuation
GlaxoSmithKline EV to EBITDA ratio is 4.92, with an EV/FCF ratio of 8.78.
EV to Sales1.57
EV to EBITDA4.92
EV to Free Cash Flow8.78
EV to Operating Cash Flow7.16
Balance Sheet
GlaxoSmithKline has $4.54B in cash and marketable securities with $25.13B in debt, giving a net cash position of -$20.59B billion.
Cash & Marketable Securities$4.54B
Total Debt$25.13B
Net Cash-$20.59B
Net Cash Per Share-$10.16
Tangible Book Value Per Share-$7.63
Margins
Gross margin is 72.74%, with operating margin of 25.52%, and net profit margin of 17.50%.
Gross Margin72.74%
Operating Margin25.52%
Pretax Margin22.66%
Net Profit Margin17.50%
EBITDA Margin31.84%
EBIT Margin24.76%
Analyst Forecast
The average price target for GlaxoSmithKline is $54.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$54.00
Price Target Upside-7.46% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast9.19%
EPS Growth Forecast98.98%